Safety Considerations So far, BPC-157 has shown a strong safety profile in preclinical and limited human studies
NICE guidance (NG28) recommends GLP-1 receptor agonists like Trulicity as a treatment option for adults with type 2 diabetes when: Triple therapy is required (in combination with metformin and another oral drug) The patient has a BMI 35 kg/m (or lower thresholds for some ethnic groups) with specific psychological or medical problems associated with obesity Insulin therapy would have significant occupational implications or weight loss would benefit other obesity-related comorbidities Importantly, NICE recommends continuing GLP-1 receptor agonist treatment only if the patient has had a beneficial metabolic response (a reduction of at least 11 mmol/mol [1.0%] in HbA1c and weight loss of at least 3% of initial body weight) after 6 months
[Google Scholar] 273.Vainchtein ID, Molofsky AV
Theres no wait for a specialist referral, no arguing with insurance companies over prior authorizations, and no driving across town for a 10-minute appointment
Patients with Type 2 diabetes have many other drug treatment options, including other GLP-1 receptor agonists like Mounjaro (tirzepatide) and Trulicity (dulaglitude)
Anecdotally reported by users to improve sleep quality and recovery, consistent with growth hormone's established role in promoting slow-wave sleep, though this specific outcome has not been directly tested in CJC-1295 clinical trials
